Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | CFTR | P13569 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10360804 | 0.90 | ALDH1A1 (0.77) | ALDH1A1LMNAKDM4EGLATSHR | |
| SCHEMBL383349 | 0.89 | ALDH1A1 (0.66) | ALDH1A1LMNAKDM4EGLATSHR | |
| SCHEMBL3554041 | 0.88 | ALDH1A1 (0.64) | ALDH1A1LMNAKDM4EGLATSHR | |
| SCHEMBL2655008 | 0.86 | ALDH1A1 (0.62) | ALDH1A1LMNAKDM4EGLATSHR | |
| SCHEMBL5253878 | 0.86 | ALDH1A1 (0.62) | ALDH1A1LMNAKDM4EGLATSHR | |
| SCHEMBL1629682 | 0.85 | ALDH1A1 (0.70) | ALDH1A1LMNAKDM4EGLATSHR | |
| SCHEMBL29875722 | 0.85 | ALDH1A1 (0.70) | ALDH1A1LMNAKDM4EGLATSHR | |
| SCHEMBL6941818 | 0.85 | ALDH1A1 (0.70) | ALDH1A1LMNAKDM4EGLATSHR | |
| SCHEMBL2093835 | 0.85 | ALDH1A1 (0.64) | ALDH1A1LMNAKDM4EGLATSHR | |
| SCHEMBL18095192 | 0.84 | ALDH1A1 (0.59) | ALDH1A1LMNAKDM4EGLATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102850221-A | Synthesis method for 2-(2-bromoethyl)benzoic acid methyl ester | SHENGSHI TAIKE BIOMEDICAL TECHNOLOGY SUZHOU CO LTD | 2013-01-02 | — | — | CN | claimed |
| CN-115260165-A | Benzo nitrogen-containing five-membered heterocyclic compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2022-11-01 | — | — | CN | disclosed |
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550746-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2015-08-06 | — | — | US | disclosed |
| US-8927544-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927544-B2 | Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130231338-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231338-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231338-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| CN-102850221-A | Synthesis method for 2-(2-bromoethyl)benzoic acid methyl ester | SHENGSHI TAIKE BIOMEDICAL TECHNOLOGY SUZHOU CO LTD | 2013-01-02 | — | — | CN | disclosed |
| CN-102850221-A | Synthesis method for 2-(2-bromoethyl)benzoic acid methyl ester | SHENGSHI TAIKE BIOMEDICAL TECHNOLOGY SUZHOU CO LTD | 2013-01-02 | — | — | CN | disclosed |
| US-8076374-B2 | Used to treat diabetic and other glucagon related metabolic disorders such as obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing; 3-{4-[1-Allyl-1-(4'-trifluoromethyl-biphenyl-4-yloxymethyl)-but-3-enyl]-benzoylamino}-propionic acid; | ELI LILLY AND COMPANY (US) | 2011-12-13 | — | — | US | disclosed |
| EP-1951659-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20080319074-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-12-25 | — | — | US | disclosed |
| EP-1951659-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly & Company (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007114855-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319074-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | ALDH1A1 2897/4885LMNA 3722/4885KDM4E 2271/4885 |
| US-20150218119-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CCR5 | ALDH1A1 1991/4885LMNA 4781/4885KDM4E 4701/4885 |
| US-20130231338-A1 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CCR5 | ALDH1A1 1991/4885LMNA 4781/4885KDM4E 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.